Strategic Collaboration Formed Between Champions Oncology and Caris Life Sciences
Hackensack, NJ – July 10, 2015 – Champions Oncology, Inc. (OTC : CSBR) a company engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs, today announced that a strategic collaboration with Caris Life Sciences has been formed.
As a result, Champions Oncology will deliver Caris Molecular Intelligence tumor profiling services in the UK. Caris Molecular Intelligence provides the healthcare information and comprehensive tumor profiling services of Caris Life Sciences. With more than 70,000 patients profiled, the service provides oncologists with the most clinically-actionable treatment options available to personalize cancer care. Using a variety of advanced profiling technologies to assess relevant biological changes in each patient’s tumor, Caris Molecular Intelligence connects biomarker data generated from a tumor with biomarker-drug associations supported by evidence in the relevant clinical literature.
Champions Oncology enables the personalized use of oncology drugs by creating in vivo tumor models that can be used to predict therapeutic efficacy. Live tumors from patients are implanted in mouse avatar models (also called patient-derived xenograft or PDX models) and tested against a range of single-agent, combination chemotherapy regimens, targeted biologic drugs and antiangiogenics, as appropriate. The results can predict the likely success of therapy. The Champions TumorGraft PDX process allows for informed decisions in individualized cancer care and fully compliments the services of Caris Molecular Intelligence.